

European Heart Journal

Volume 43 No. 10 March 2022

ISSUE @ A GLANCE



Personalized antithrombotic treatment of cardiovascular disease: a glimpse into the future based on current knowledge

F. Crea 925

CardioPulse

The value of 4D flow MRI in cardiac assessment

M. Nicholls 930

The long journey of interleukin-1 in acute and recurrent pericarditis

A. Bonaventura 933

Patient perspectives: how a quest for better recognition and care united four women from three different continents

J. Ozkan 935

Weekly Journal Scan

Give genotype-guided dual antiplatelet therapy a second CHANCE

G. Liuzzo and C. Patrono 938

FOCUS ISSUE ON THROMBOSIS AND ANTITHROMBOTIC TREATMENT

STATE OF THE ART REVIEW

Towards personalized antithrombotic management with drugs and devices across the cardiovascular spectrum

T.F. Lüscher, A. Davies, J.H. Beer, M. Valgimigli, C.A. Nienaber, J.A. Camm, I. Baumgartner, H.-C. Diener, and S.V. Konstantinides 940

CLINICAL RESEARCH

Comparative effects of guided vs. potent P2Y₁₂ inhibitor therapy in acute coronary syndrome: a network meta-analysis of 61 898 patients from 15 randomized trials*

M. Galli, S. Benenati, F. Franchi, F. Rollini, D. Capodanno, G. Biondi-Zoccai, G.M. Vescovo, L.H. Cavallari, B. Bikdeli, J. ten Berg, R. Mehran, C.M. Gibson, F. Crea, N.L. Pereira, D. Sibbing, and D.J. Angiolillo 959

Editorial

Time for a paradigm shift? Making the case for tailored selection of antiplatelet therapy

M.L. O'Donoghue and N.A. Marston 968

Atherothrombotic factors and atherosclerotic cardiovascular events: the multi-ethnic study of atherosclerosis

A.P. DeFilippis, P.J. Trainor, G. Thanassoulis, L.C. Brumback, W.S. Post, M.Y. Tsai, and S. Tsimikas 971

Editorial

Thrombosis and fibrinolysis in atherosclerotic cardiovascular disease: it takes two to tango

A. Fedorowski, J.M. Siller-Matula, and G. Patti 982

Ciraparantag reverses the anticoagulant activity of apixaban and rivaroxaban in healthy elderly subjects

J. Ansell, S. Bakhru, B.E. Laulicht, G. Tracey, S. Villano, and D. Freedman 985

Editorial

Ciraparantag as a potential universal anticoagulant reversal agent

N.C. Chan and J.I. Weitz 993



Dual antithrombotic treatment in chronic coronary syndrome: European Society of Cardiology criteria vs. CHADS-P₂A₂RC score

M. Würtz, K.K.W. Olesen, M.B. Mortensen, J.W. Eikelboom, M.A. Mohammad, D. Erlinge, S.D. Kristensen, and M. Maeng

996

Editorial

The CHADS-P₂A₂RC score: ready to guide the selection of treatment?

J. Mehilli and M. Winhard

1005

VIEWPOINT

Heparin use in acute coronary syndromes and cardiovascular interventions: habit or evidence based?

S. Tan, H.D. White, and J. Layland

1008

DISCUSSION FORUM

Myocardial infarction after elective percutaneous coronary intervention—which cardiac troponin cut-off to use?

K.M. Eggers, S.K. James, and B. Lindahl

1012

Appropriate criteria for the definition of Type 4a MI

J. Silvain, D. Hausenloy, and M. Zeitouni

1013

CARDIOVASCULAR FLASHLIGHT

When the solution becomes the problem: left atrial appendage occlusion device-related thrombus after 5 years

R. Nasser, N. Meyten, P. Vermeersch, and E.A. Prihadi

1015

*This paper is Editor's Choice and is available free online at <https://academic.oup.com/eurheartj>

Open Access Paper

For the podcast associated with this article, please visit <https://academic.oup.com/eurheartj/pages/Podcasts>



www.eurheartj.org